GIST PDX Models

While the genetic reasons behind imatinib acquired resistance in gastrointestinal stromal tumors (GIST) are well known, the development of new agents to overcome this resistance has been limited. This is due to a lack of preclinical models which fully recapitulate the complex interplay of KIT primary and secondary mutations seen in the clinical population. CrownBio provides the world’s most comprehensive panel of GIST patient-derived xenograft (PDX) models, ideal for the preclinical evaluation of novel therapies to circumvent imatinib resistance. More

PDX offer the most translational preclinical model for efficacy screening in cancer drug development. Derived directly from patient tumors and never adapted to grow in vitro, PDX models reflect the heterogeneity and diversity of the human patient population. PDX give you an accurate, predictive model of how your treatment will perform, well before entering into expensive clinical trials. CrownBio’s HuPrime® PDX models are well characterized for pathology, growth characteristics, and are also genetically/genomically annotated for gene expression, gene copy number, mutations, and fusions.
MODEL NUMBER CANCER SUBTYPE # per page
GS11327 GISTCLICK TO VIEW
GS11328 GISTCLICK TO VIEW
GS11329 GISTCLICK TO VIEW
GS11331 GISTCLICK TO VIEW
GS11339 GISTCLICK TO VIEW
GS11342 GISTCLICK TO VIEW
GS11351 GISTCLICK TO VIEW
GS11353 GISTCLICK TO VIEW
GS11354 GISTCLICK TO VIEW
GS11360 GISTCLICK TO VIEW
GS5106 GIST (cKIT mut)CLICK TO VIEW
GS5107 GIST (cKIT mut)CLICK TO VIEW
GS5108 GIST (cKIT mut)CLICK TO VIEW